|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Immunostaining was performed for Netrin-1 (deleted in colorectal carcinoma [DCC], UNC5A) and GDNF receptors (rearranged during transfection [Ret], glycosylphosphatidylinositol-linked cell surface receptors [GFRα1, GFRα2, GFRα3]).
|
30811036 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.
|
29538669 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To investigate therapeutic options to CRC patient with a RET fusion, we performed cell viability assays using the PDCs.
|
30210625 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using a genomics guided outlier approach, we identified 4 RET fusion PDX models with 3 different fusion partners (KIF5B, CCDC6, and NCOA4) in both non-small cell lung cancer and colorectal cancer.
|
30038711 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
We recently described RET promoter CpG island methylation as a potential prognostic marker in stage II colorectal cancer (CRC) patients of two independent series.
|
27118999 |
2016 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This is the first characterization of RET fusions in CRC patients and highlights the therapeutic significance of prospective comprehensive genomic profiling in advanced CRC.
|
26078337 |
2015 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This review will describe how receptors such as deleted in colorectal carcinoma (DCC), uncoordinated 5 (UNC5), rearranged during transfection (RET) or TrkC constrain CRC progression and how this dependence receptor paradigm may open up therapeutical perspectives.
|
25163468 |
2014 |
|
Colorectal Carcinoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
RET methylation may serve as a useful and robust tool for clinical practice to identify high-risk stage II CRC patients with a poor prognosis.This merits further investigation.
|
24560444 |
2014 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, in support of a tumor suppressor function of RET, mutant RET has also been found in primary colorectal cancer.
|
22751117 |
2013 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal cancer and 24 non-small cell lung cancer formalin-fixed paraffin-embedded tissue specimens identified at least one clinically relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorectal cancer sample and KIF5B-RET in a lung adenocarcinoma.
|
22327622 |
2012 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Genomic and epigenomic integration identifies a prognostic signature in colon cancer.
|
21278247 |
2011 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mutations of RET are associated to a subset of colorectal cancer and are commonly found in hereditary and sporadic thyroid cancer.
|
21110809 |
2011 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis.
|
18507500 |
2008 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here we evaluate the consequence of NMD activity in colorectal cancers (CRCs) showing microsatellite instability (MSI) whose progression is associated with the accumulation of PTC-mRNAs encoding immunogenic proteins due to frameshift mutations in coding repeat sequences.
|
18612427 |
2008 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|